An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy

被引:21
作者
Reimers, Arne [1 ]
Ljung, Hanna [2 ,3 ]
机构
[1] Dept Clin Chem & Pharmacol, Div Lab Med, S-22185 Lund, Sweden
[2] Skane Univ Hosp, Dept Neurol & Rehabil Med, Lund, Sweden
[3] Lund Univ, Dept Clin Neurosci Lund, Fac Med, Lund, Sweden
关键词
Cognitive adverse effect; drug safety; epilepsy; gastrointestinal adverse effects; long-term efficacy; mechanism of action; monotherapy; pharmacokinetics; psychiatric adverse effects; retention rate; ANTIEPILEPTIC DRUGS; DOUBLE-BLIND; ADJUNCTIVE ZONISAMIDE; REFRACTORY EPILEPSY; PHASE-III; RETENTION RATES; OPEN-LABEL; CHILDREN; SAFETY; MONOTHERAPY;
D O I
10.1080/14656566.2019.1595584
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: About 70 million people worldwide are estimated to suffer from epilepsy. Despite a large variety of old and new antiepileptic drugs on the market, about 30% of people with epilepsy do not become seizure-free with medical treatment. This is a major individual and public health burden. Most of these difficult-to-treat patients are having focal seizures. Zonisamide is effective against focal seizures in adults and children and, thus, a therapeutic option for such patients. Its safety profile needs special attention.Areas covered: Herein, the authors discuss the pharmacology, clinical efficacy and the adverse effects of zonisamide. The article is derived from clinical trial data, long-term studies, meta-analyses, review articles, text books, webpages, and official license information.Expert opinion: Zonisamide has proven to be efficacious in focal epilepsy in children and adults, although it is not more effective than carbamazepine or other antiepileptic drugs. It is also effective in generalized epilepsy and in several other conditions of the CNS. Its safety profile may prevent it from becoming a first-line drug for focal epilepsy or any other indication.
引用
收藏
页码:909 / 915
页数:7
相关论文
共 73 条
[1]   Patient-reported cognitive side effects of antiepileptic drugs: Predictors and comparison of all commonly used antiepileptic drugs [J].
Arif, Hiba ;
Buchsbaum, Richard ;
Weintraub, David ;
Pierro, Joanna ;
Resor, Stanley R., Jr. ;
Hirsch, Lawrence J. .
EPILEPSY & BEHAVIOR, 2009, 14 (01) :202-209
[2]   The Use of Antiepileptics in Migraine Prophylaxis [J].
Bagnato, Francesca ;
Good, Janine .
HEADACHE, 2016, 56 (03) :603-615
[3]   Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: Results of a phase III, randomized, double-blind study [J].
Baulac, Michel ;
Patten, Anna ;
Giorgi, Luigi .
EPILEPSIA, 2014, 55 (10) :1534-1543
[4]   Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial [J].
Baulac, Michel ;
Brodie, Martin J. ;
Patten, Anna ;
Segieth, Joanna ;
Giorgi, Luigi .
LANCET NEUROLOGY, 2012, 11 (07) :579-588
[5]  
Bialer M, 2017, EPILEPSIA, V58, P181, DOI [10.1111/epi.13634, 10.1111/epi.14557]
[6]   Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System [J].
Borrelli, Eric P. ;
Lee, Erica Y. ;
Descoteaux, Andrew M. ;
Kogut, Stephen J. ;
Caffrey, Aisling R. .
EPILEPSIA, 2018, 59 (12) :2318-2324
[7]   Zonisamide add-on therapy for focal epilepsy [J].
Brigo, Francesco ;
Lattanzi, Simona ;
Igwe, Stanley C. ;
Behzadifar, Masoud ;
Bragazzi, Nicola Luigi .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (10)
[8]  
Brodie MJ, 2009, EPILEPSIA, V50, P411
[9]  
Brodie MJ, 2005, EPILEPSIA, V46, P31
[10]  
Cardarelli WJ, 2010, AM J MANAG CARE, V16, pS331